Form 4: Phyllis Yale Reports Acquisition of Deferred Share Units in Bristol-Myers Squibb

Director Phyllis Yale reports the acquisition of deferred share units in Bristol-Myers Squibb, convertible to common stock upon future settlement.

Summary

• Phyllis Yale, a director of Bristol-Myers Squibb, reported the acquisition of 573.865 deferred share units on March 31, 2025.
• These units will be converted into shares of common stock upon settlement, which occurs when Yale ceases to be a director or at a previously specified future date.
• The price per unit is $60.99.
• Following the transaction, Yale beneficially owns 35,251.068 shares, including deferred compensation and reinvested dividends.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of a transaction by a company director. The acquisition of deferred share units can be seen as a positive sign of alignment with the company's future, but it's a routine event.

Positives

• The acquisition of deferred share units indicates a continued investment and alignment of interests between the director and the company.
• The reinvestment of dividends into deferred compensation further demonstrates a long-term commitment to Bristol-Myers Squibb.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which will occur when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers. These filings are closely watched by investors to gauge sentiment and potential future actions of key individuals within the company.

Comparison to Industry Standards

• Comparing Phyllis Yale's holdings and transactions to those of other directors in similar large-cap pharmaceutical companies like Johnson & Johnson (JNJ) or Pfizer (PFE) could provide context.
• Reviewing the compensation structures and equity ownership guidelines of these companies can offer insights into whether Yale's holdings are typical or exceptional.
• Analyzing the frequency and size of insider transactions in these peer companies can help determine if Yale's activity is aligned with industry norms.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals continued investment by a director.
• There is no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, Bristol-Myers Squibb, Deferred Share Units, Director, Phyllis Yale, Beneficial Ownership, BMY